TrialFrontiers of medicine2022

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.

Yuntao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.